May 5, 2025

Genomate Health Appoints CEO to Lead Commercial Expansion

May 5, 2025

Genomate Health, a precision oncology company developing a new category of computational tools for Digital Drug Assignment (DDA) - a method using advanced computational reasoning to automatically match the most effective and personalized drug treatment to an individual patient's unique biological and clinical profile - announced today a major step in its growth with the appointment of CEO Nabil Hafez.

Other Media Coverage

See all

Genomate Health Adds Intelligene Healthcare as India Distributor

January 23, 2024

Read Article

DiMe and Moffitt Cancer Center to Co-Host Cancer Moonshot's New CancerX Public-Private Partnership

March 23, 2023

Read Article

Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 4, 2024

Read Article

Other Resources

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.